))
Episode 38. GVHD Prophylaxis in Allo-Transplant with Dr. Shernan Holtan
Manage episode 396308503 series 3369804
Contenu fourni par Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
In this episode, we talk about GVHD prophylaxis, including recent data on post-transplant cyclophosphamide and abatacept with Dr. Shernan Holtan from the University of Minnesota.
Here are the key trials we discussed:
1. BMT CTN 1203 trial: Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of GVHD in allogeneic transplantation.
https://pubmed.ncbi.nlm.nih.gov/30824040/
2. BMT CTN 1703 study: Post-Transplantation Cyclophosphamide-Based GVHD prophylaxis
https://pubmed.ncbi.nlm.nih.gov/37342922/
3. Patient-Reported Outcomes of BMT CTN 1703
https://ash.confex.com/ash/2023/webprogram/Paper187859.html
4. Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil
https://pubmed.ncbi.nlm.nih.gov/37311510/
5. BMT CTN 1301 trial: Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies
https://pubmed.ncbi.nlm.nih.gov/34855460/
6. Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD (ABA2)
https://pubmed.ncbi.nlm.nih.gov/33449816/
7. Aurora Kinase a Inhibition for Gvhd and Relapse Prevention after Allogeneic HCT: Phase I Trial in Combination with Ptcy/Sirolimus
48 episodes
Partager
